Recent advances are revolutionizing patient care, and in some cases, like cell and gene therapies, bringing us closer to cures. The revision of this legislation is a prime opportunity to shape the life sciences ecosystem in Europe, allowing us to expand the best care for patients. Policymakers are attempting to address two key issues with these policies: immediate budgetary pressures and equitable patient access to medicines. The findings show Europe’s share of global R&D investment is predicted to reduce by a third (from 32 percent of global R&D expenditure to 21 percent) by 2040. Available at: https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/germany-belgium-and-france-among-those-hit-hardest-as-commission-s-pharma-legislation-proposals-risk-europe-losing-a-third-of-its-share-of-global-rd-by-2040/# Last accessed Nov 23[xii] Attracting Life Science Investments in Europe Report available at https://www.europabio.org/wp-content/uploads/2023/11/Life-Science-Attractiveness-2023-November-22-Final-Final_LR2.pdf last accessed Nov 2023

Source: New York Times December 11, 2023 04:11 UTC